The global anti-epileptic drugs for pediatrics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Antiepileptic drugs (AEDs) are commonly known as anticonvulsants or antiseizure drugs. These drugs are used in the treatment of epileptic seizures. Epilepsy is a central neurological disorder that causes brain activity to become abnormal and further causes seizures or periods of unusual behaviour, sensations and sometimes loss of awareness. Additionally, these drugs are also used to stabilize the mood along with the treatment of bipolar disorders or neuropathic pain. The major factor driving the demand for the global anti-epileptic drugs for pediatrics market during the forecast period is the increasing prevalence of epilepsy across the globe.
According to the World Health Organization (WHO), in 2019, epilepsy is one of the most common neurological diseases globally with around 50 million people diagnosed with it. Further, as per the Healthy Children Org, in 2021, almost 3 million Americans have epilepsy. Out of which 450,000 are under 17 years old. Hence, the increasing prevalence of epilepsy among pediatrics is driving the demand for anti-epileptic drugs which in turn is driving the growth of the market.
To Request a Sample of our Report on Anti-Epileptic Drugs For Pediatrics Market: https://www.omrglobal.com/request-sample/anti-epileptic-drugs-for-pediatric-market
Some major players in the market include GlaxoSmithKline plc, Novartis International AG, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Eisai Co. announced that its anti-epileptic drug (AED) Fycompa has obtained two additional approvals in China from the National Medical Products Administration. The approval was for the monotherapy for partial-onset seizures and an adjunctive treatment/a monotherapy for the pediatric indication for partial-onset seizures with epilepsy in patients of age 4 years and older.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Drug Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– GlaxoSmithKline plc, Novartis International AG, and Pfizer Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Anti-Epileptic Drugs For Pediatrics Market is Available @ https://www.omrglobal.com/industry-reports/anti-epileptic-drugs-for-pediatric-market
Global Anti-Epileptic Drugs For Pediatrics Market Report by Segment
By Drug Type
- 1st Generation
- 2nd Generation
- 3rd Generation
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Anti-Epileptic Drugs For Pediatrics Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
